Collegium Pharmaceutical, Inc. Revenue from Contract with Customer, Including Assessed Tax
Collegium Pharmaceutical, Inc. (COLL) reported Revenue from Contract with Customer, Including Assessed Tax of $72.94 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2019-11-06
- Collegium Pharmaceutical, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $72.94M, a 3.94% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-06-30 was $75.04M, a 2.71% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-03-31 was $74.52M, a 16.89% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2018-12-31 was $73.43M, a 580.26% increase year-over-year.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, including assessed tax for fiscal 2018 was $280.41M, a 884.73% increase from fiscal 2017.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, including assessed tax for fiscal 2017 was $28.48M, a 1564.29% increase from fiscal 2016.
- Collegium Pharmaceutical, Inc. revenue from contract with customer, including assessed tax for fiscal 2016 was $1.71M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2019-09-30 | $72.94M 10-Q · filed 2019-11-06 | $147.98M derived: sum of 2 quarters · filed 2019-11-06 | $222.50M 10-Q · filed 2019-11-06 | $295.93M derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | $75.04M 10-Q · filed 2019-08-07 | $149.56M 10-Q · filed 2019-08-07 | $222.98M derived: sum of 3 quarters · filed 2019-08-07 | $293.16M derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-03-31 | $74.52M 10-Q · filed 2019-05-08 | $147.94M derived: sum of 2 quarters · filed 2019-05-08 | $218.12M derived: sum of 3 quarters · filed 2019-11-06 | $291.18M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-12-31 | $73.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $143.60M derived: sum of 2 quarters · filed 2019-11-06 | $216.66M derived: sum of 3 quarters · filed 2019-11-06 | $280.41M 10-K · filed 2019-02-27 |
| 2018-09-30 | $70.18M 10-Q · filed 2019-11-06 | $143.24M derived: sum of 2 quarters · filed 2019-11-06 | $206.99M 10-Q · filed 2019-11-06 | $217.78M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $73.06M 10-Q · filed 2019-08-07 | $136.81M 10-Q · filed 2019-08-07 | $147.60M derived: sum of 3 quarters · filed 2019-08-07 | $159.55M derived: sum of 4 quarters · filed 2019-08-07 |
| 2018-03-31 | $63.75M 10-Q · filed 2019-05-08 | $74.54M derived: sum of 2 quarters · filed 2019-05-08 | $86.49M derived: sum of 3 quarters · filed 2019-05-08 | $90.05M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $22.74M derived: sum of 2 quarters · filed 2019-02-27 | $26.30M derived: sum of 3 quarters · filed 2019-02-27 | $28.48M 10-K · filed 2019-02-27 |
| 2017-09-30 | $11.95M 10-Q · filed 2018-11-08 | $15.51M derived: sum of 2 quarters · filed 2018-11-08 | $17.68M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $3.56M 10-Q · filed 2018-08-08 | $5.73M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $2.17M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | $1.71M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |